These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 27563744)

  • 1. 2017 Clinical trials update: Innovations in hemophilia therapy.
    Hartmann J; Croteau SE
    Am J Hematol; 2016 Dec; 91(12):1252-1260. PubMed ID: 27563744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The More Recent History of Hemophilia Treatment.
    Franchini M; Mannucci PM
    Semin Thromb Hemost; 2022 Nov; 48(8):904-910. PubMed ID: 36108649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving Complexity in Hemophilia Management.
    Croteau SE
    Pediatr Clin North Am; 2018 Jun; 65(3):407-425. PubMed ID: 29803274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
    Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
    Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic infusion regimens in the management of hemophilia.
    Ljung RC
    Thromb Haemost; 1999 Aug; 82(2):525-30. PubMed ID: 10605746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs for the treatment of hemophilia A and B.
    Morfini M; Zanon E
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):301-13. PubMed ID: 27547884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of pharmacologic options for the treatment of persons with hemophilia.
    Franchini M; Mannucci PM
    Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of recombinant factor replacement for hemophilia.
    Sankar AD; Weyand AC; Pipe SW
    Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and Management of Bleeding Episodes in Children with Hemophilia.
    Ljung RCR
    Paediatr Drugs; 2018 Oct; 20(5):455-464. PubMed ID: 30128815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long and short of it: using the new factor products.
    Dunn A
    Hematology Am Soc Hematol Educ Program; 2015; 2015():26-32. PubMed ID: 26637697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.
    Ducore JM; Miguelino MG; Powell JS
    Expert Rev Hematol; 2014 Oct; 7(5):559-71. PubMed ID: 25142322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma derivatives: new products and new approaches.
    Sauna ZE; Pandey GS; Jain N; Mahmood I; Kimchi-Sarfaty C; Golding B
    Biologicals; 2012 May; 40(3):191-5. PubMed ID: 22239993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Congenital hemophilia: a new treatment paradigm].
    Shima M
    Rinsho Ketsueki; 2019; 60(6):647-658. PubMed ID: 31281158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting TFPI for hemophilia treatment.
    Peterson JA; Maroney SA; Mast AE
    Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S28-30. PubMed ID: 27207418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges.
    Trinchero A; Sholzberg M; Matino D
    Hamostaseologie; 2020 Aug; 40(3):311-321. PubMed ID: 32726826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products.
    Berntorp E; Andersson NG
    Semin Thromb Hemost; 2016 Jul; 42(5):518-25. PubMed ID: 27096762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?
    Ellsworth P; Ma A
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):219-225. PubMed ID: 34889356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of recombinant coagulation factors in treating hemophilia.
    Morfini M; Rapisarda CAP
    Expert Opin Drug Saf; 2019 Feb; 18(2):75-85. PubMed ID: 30681006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.